Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesilate (i.e. methanesulfonate) salt is sold under tradenames including Edronax®, Norebox®, Prolift® or Vestra®. Chemically it is (±)-(2R*)-2-[(αR*)-α-(o-ethoxyphenoxy)benzyl]morpholine.

Unlike most antidepressants on the market, Reboxetine is a noradrenaline reuptake inhibitors (NARI); it does not inhibit the reuptake of serotonin, though it can be safely combined with an SSRI. Reboxetine is currently marketed by Pharmacia & Upjohn.

By mid-2001, reboxetine was licensed worldwide in over 50 countries, including Italy, Germany and the UK. In May 2001, however, the FDA declined Pharmacia's license application for the American market. As such it is yet to be available in the US.

Common side effects of reboxetine include: dry mouth, constipation, headache, drowsiness, dizziness, excessive sweating and insomnia.

Reboxetine has a relatively short elimination half life of 12.5 hours and therefore is often given twice daily.